PGIM Jennison Health Sciences Fund - Class R (PJHRX)
Fund Assets | 2.61B |
Expense Ratio | 1.48% |
Min. Investment | $0.00 |
Turnover | n/a |
Dividend (ttm) | 5.20 |
Dividend Yield | 18.45% |
Dividend Growth | 171.88% |
Payout Frequency | Annual |
Ex-Dividend Date | Dec 20, 2024 |
Previous Close | 28.56 |
YTD Return | -9.99% |
1-Year Return | -0.85% |
5-Year Return | 53.93% |
52-Week Low | n/a |
52-Week High | n/a |
Beta (5Y) | n/a |
Holdings | 49 |
Inception Date | Feb 3, 2012 |
About PJHRX
The Fund's investment strategy focuses on Health/Biotech with 1.49% total expense ratio. The minimum amount to invest in Prudential Sector Funds, Inc: PGIM Jennison Health Sciences Fund; Class R Shares is $0 on a standard taxable account. Prudential Sector Funds, Inc: PGIM Jennison Health Sciences Fund; Class R Shares seeks long-term capital appreciation. PJHRX invests primarily in equity-related securities of U.S. firms engaged in the following industries: hospitals, nursing and residential care, health and medical insurance carriers, pharmaceutical and medicine companies, and medical equipment firms.
Performance
PJHRX had a total return of -0.85% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.82%.
Top 10 Holdings
50.74% of assetsName | Symbol | Weight |
---|---|---|
Eli Lilly and Company | LLY | 14.60% |
UnitedHealth Group Incorporated | UNH | 5.66% |
Vertex Pharmaceuticals Incorporated | VRTX | 4.85% |
argenx SE | ARGX | 4.47% |
AstraZeneca PLC | AZN | 4.18% |
Neurocrine Biosciences, Inc. | NBIX | 3.68% |
Bristol-Myers Squibb Company | BMY | 3.58% |
Boston Scientific Corporation | BSX | 3.32% |
CVS Health Corporation | CVS | 3.31% |
Danaher Corporation | DHR | 3.07% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 20, 2024 | $5.20167 | Dec 20, 2024 |
Dec 20, 2023 | $1.91322 | Dec 20, 2023 |
Dec 20, 2022 | $0.61624 | Dec 20, 2022 |
Dec 20, 2021 | $14.02528 | Dec 20, 2021 |
Dec 20, 2019 | $1.43164 | Dec 20, 2019 |
Dec 20, 2018 | $4.77761 | Dec 20, 2018 |